BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
17 November 2011
Pial Ganguli
Please Login to read the full article.
17 November 2011
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA rejects AZ/BMS diabetes drug dapagliflozin
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
- US Capitol Capsule: FDA cuts shortages, improves user fee goals, while Medicare makes big bust
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
